LYMPHEDEMA*
Lymphedema is a chronic inflammatory disorder caused by ineffective fluid uptake by the lymphatic system, with effects mainly on the lower limbs. This pathology may be classified as primary when caused by genetic mutations with typical Mendelian inheritance, or secondary when it is acquired following injury, infection, or surgery. The prevalence of primary and secondary lymphedema is 1/100,000 and 1/1000, respectively. Overall, lymphedema affects 140–250 million people worldwide.
The study of the biological basis of lymphedema could open new paths toward targeted therapies. This is possible using omics analysis aimed at identifying new associated genetic variants, new biomarkers, or through the study of the molecular pathways involved. Our research aims to use these data to then use natural molecules, such as olive tree polyphenols and bioflavonoids from citrus fruits, that may be able to modulate this pathology and that are contained in typical plants of the Mediterranean diet.
MORE RILEVANT ARTICLE PUBLISHED IN PUBMED BY THE MAGISNAT GROUP*:
Click for the link PubMed:
- “Improvement of quality of life by intake of hydroxytyrosol in patients with lymphedema and association of lymphedema genes with obesity”;
- “Effect of a dietary supplement on the reduction of lymphedema- progression in mouse tail-cut model”;
- “Study of a supplement and a genetic test for lymphedema management”;
- “Molecular pathways involved in lymphedema: Hydroxytyrosol as a candidate natural compound for treating the effects of lymph accumulation”;
- “Imbalance between Expression of FOXC2 and Its lncRNA in Lymphedema-Distichiasis Caused by Frameshift Mutations“;
- “Increasing evidence of hereditary lymphedema caused by CELSR1 loss-of-function variants“;
- “Low Efficacy of Genetic Tests for the Diagnosis of Primary Lymphedema Prompts Novel Insights into the Underlying Molecular Pathways“;
- “Genetic Screening in a Large Cohort of Italian Patients Affected by Primary Lymphedema Using a Next Generation Sequencing (NGS) Approach”.
- “Dietary supplements in lymphedema”
- “CDH5, a Possible New Candidate Gene for Genetic Testing of Lymphedema”
- “Low Efficacy of Genetic Tests for the Diagnosis of Primary Lymphedema Prompts Novel Insights into the Underlying Molecular Pathways”
*“None of the reported studies or the patent can be used to claim the properties of dietary supplements. Dietary supplements do not possess any therapeutic or preventive properties.”
